Sex Differences in Critical-Illness Metabolism: Mechanisms, Clinical Implications, and Emerging Insights

Abstract

Critical illness triggers profound alterations in human metabolism, with sex-based differences increasingly recognized as significant modulators of both pathophysiology and clinical outcomes. This review synthesizes current evidence on how biological sex influences metabolic response during critical illness, encompassing mechanisms, epidemiology, risk factors, clinical features, diagnostic nuances, management, and recent advances. Insights from recent multicenter studies and consensus guidelines are integrated to inform personalized therapeutic strategies, aiming to optimize outcomes for both male and female patients in intensive care.

Introduction

Sex differences in medicine have gained heightened attention, particularly in critical care where metabolic responses to severe physiological stress are pivotal determinants of morbidity and mortality. While the acute phase of critical illness characterized by systemic inflammation, catabolism, and altered substrate utilization affects all patients, data increasingly suggest that male and female patients exhibit distinct metabolic trajectories. Understanding these differences is essential for tailoring interventions and improving outcomes in the intensive care unit (ICU) setting. This review addresses the epidemiological, mechanistic, and clinical relevance of sex-based metabolic differences during critical illness, and provides practical implications for clinicians managing diverse patient populations.

Epidemiology / Disease Burden

The global burden of critical illness, encompassing sepsis, trauma, acute respiratory distress syndrome (ARDS), and multi-organ failure, is substantial. Epidemiological studies indicate nuanced sex-based variation in ICU admissions and outcomes. Males generally represent a higher proportion of ICU patients, possibly reflecting greater exposure to risk factors such as trauma and cardiovascular disease. However, recent registry data reveal that female patients, especially postmenopausal women, may have increased susceptibility to certain critical illnesses and distinct mortality patterns. Large-scale meta-analyses report sex-differential mortality in sepsis and ARDS, with females sometimes demonstrating relative survival advantages, particularly in premenopausal cohorts. These trends underscore the need for sex-aware epidemiological tracking and resource allocation in critical care medicine.

Pathophysiology

Sex differences in critical-illness metabolism are underpinned by complex interactions among sex hormones, immune function, and genetic factors. Estrogens modulate inflammatory responses, mitochondrial function, and substrate utilization, often conferring protective effects in premenopausal women. Conversely, testosterone and androgenic pathways may promote pro-inflammatory and catabolic states. Sex chromosomes themselves contribute to metabolic regulation, with genes on the X chromosome influencing immune cell activation and energy homeostasis. During critical illness, these factors manifest as divergent patterns in glucose, lipid, and protein metabolism. For instance, female patients may exhibit enhanced mitochondrial resilience and preserved insulin sensitivity, whereas males are more prone to hypercatabolism and insulin resistance. Animal and human studies support a role for estrogen-mediated upregulation of key antioxidant pathways and mitochondrial biogenesis, which may mitigate organ dysfunction and improve recovery trajectories.

Risk Factors

Risk factors for adverse metabolic responses in critical illness are modulated by both sex and gender. Premorbid conditions such as obesity, diabetes, and frailty display sex-specific prevalence and impact. For example, men with metabolic syndrome may experience heightened inflammatory and catabolic responses, whereas women with similar comorbidities demonstrate altered lipid metabolism and risk for stress-related hyperglycemia. Hormonal status such as menopause, polycystic ovary syndrome, or androgen deficiency further modifies metabolic vulnerability. Pharmacokinetic and pharmacodynamic differences between sexes also affect the metabolic impact of drugs commonly used in ICU care, including corticosteroids and vasopressors. Recognition of these sex-specific risk factors is crucial for individualized risk stratification and early intervention.

Clinical Features

Sex differences in clinical presentation and progression of critical illness are increasingly appreciated. Female patients may manifest subtler signs of sepsis or organ dysfunction, potentially leading to delayed diagnosis. Metabolic derangements, such as stress hyperglycemia or refeeding syndrome, may also present differently, with some studies suggesting that women are more susceptible to hypoglycemia during intensive insulin therapy. Furthermore, muscle wasting and ICU-acquired weakness appear more pronounced in male patients, likely reflecting differences in muscle mass, hormonal milieu, and catabolic drive. These distinctions necessitate heightened clinical vigilance and sex-specific monitoring strategies in the ICU environment.

Diagnosis

Diagnosis of metabolic disturbances in critical illness should consider sex-based reference ranges and physiologic variability. Biomarkers such as lactate, procalcitonin, and C-reactive protein may exhibit different baseline and dynamic responses in males versus females. Assessment of nutritional status, body composition, and substrate utilization through indirect calorimetry or bioimpedance analysis should account for sex-specific normal values. Emerging omics-based diagnostics, including metabolomics and proteomics, hold promise for identifying sex-specific metabolic signatures predictive of organ dysfunction or recovery potential. Incorporating sex as a biological variable enhances diagnostic precision and supports more nuanced prognostication.

Treatment & Management

Current management strategies for metabolic derangements in critical illness remain largely sex-neutral; however, evidence supports the benefit of individualized approaches. Nutritional support should be tailored to sex-specific energy expenditure and substrate needs. Female patients may benefit from higher lipid intake or antioxidant supplementation, while male patients may require strategies to mitigate muscle catabolism, including optimized protein provision and early mobilization. Glycemic control protocols should be adjusted for differential risks of hypoglycemia or hyperglycemia. Pharmacologic therapies, such as corticosteroids and immunomodulators, should consider sex-dependent responses to minimize adverse effects. Multidisciplinary care teams should integrate sex-based considerations into routine assessment and management pathways.

Recent Advances / Emerging Therapies

Recent advances include the development of sex-specific risk prediction models for ICU outcomes, and clinical trials evaluating hormonal therapies such as selective estrogen receptor modulators or androgen blockade in critical illness. Omics technologies have enabled identification of sex-dependent metabolic pathways amenable to targeted intervention. Research into sex-specific responses to mitochondrial protectants, immunonutrition, and muscle-preserving agents is ongoing. Precision medicine approaches leveraging sex as a key biological variable are beginning to inform experimental interventions, with early-phase studies demonstrating potential benefits in select populations. Ongoing efforts to include sex-balanced cohorts in clinical trials will further elucidate optimal therapeutic strategies.

Guideline Recommendations

Contemporary guidelines from critical care societies increasingly recognize the importance of sex differences in research and practice. The Surviving Sepsis Campaign and European Society of Intensive Care Medicine recommend sex-based subgroup analyses in clinical studies and encourage the reporting of sex-disaggregated data. Nutritional guidelines advocate for individualized assessment of metabolic needs, incorporating sex and hormonal status. There is a growing call for integration of sex-specific protocols in glycemic management, pharmacotherapy, and rehabilitation. Implementation of these recommendations remains variable, highlighting the need for ongoing education and system-level support to ensure equitable, evidence-based care.

Conclusion

Sex differences in critical-illness metabolism represent a crucial, yet underappreciated, determinant of clinical outcomes in the ICU. Advances in understanding biological mechanisms and clinical implications have begun to inform more personalized approaches to diagnosis and management. Incorporating sex as a key variable in critical care research, guideline development, and clinical practice holds promise for optimizing outcomes and advancing equity in the treatment of critically ill patients. Ongoing research and education are essential to translate these insights into routine care, ensuring that all patients benefit from the latest scientific advances in critical illness metabolism.